In order to properly evaluate the efficacy of orthopaedic procedures, rigorous, randomised controlled sham surgery trial designs are necessary. However, randomised controlled trials (RCTs) for surgery involving a placebo are ethically debated and difficult to conduct with many failing to reach their desired sample size and power. A review of the literature on barriers and enablers to recruitment, and patient and surgeons attitudes and preferences towards sham surgery trials, will help determine the characteristics necessary for successful recruitment.
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Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence. This process is more difficult however when the intervention is surgical. The surgeon can never be fully blinded and the extent to which the placebo resembles the surgery is practically and ethically problematic 4 . There is some inconsistency in the requirements of a 'sham' surgery however the definition we will use throughout this review is the same as The use of sham and placebo surgeries in surgical trials is controversial. Some commentators have argued that surgical placebos are essential, and that surgical interventions should be held to the same rigorous assessment as other medical procedures 6 7 , particularly given the expense and risks involved with the untested surgical procedures 8 9 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 5 However, others have argued it is misguided to consider sham surgery as analogous to sugar pills due to the increased risks and harm to participants without any benefit [10] [11] [12] and as such consider sham surgery to be unjustified and unethical.
These issues have become particularly prevalent in orthopaedic surgery, with the efficacy of some orthopaedic procedures being called into question. For example, recent observational studies have shown that a significant proportion of patients report no clinical meaningful improvement in pain or function after knee replacement surgery 13 14 . In a number of countries worldwide, orthopaedic surgeries are high volume and expensive procedures, with considerable risks and significant recovery times for patients 15 . In order to properly evaluate the efficacy of orthopaedic procedures, rigorous randomised controlled trial (RCT) designs, blinded through sham surgery, are necessary. There is evidence to suggest that the number of RCTs in surgery is increasing, however their use in comparison to other study types remains low 16 17 . Furthermore, RCTs for surgery involving a sham procedure are not only ethically debated but they are also difficult to conduct with most trials not reaching their desired sample size for sufficient power 8 . This is primarily due to difficulties in recruitment of both patients and surgeons. This is symptomatic of clinical trials generally, with up to 50% of funded trials not publishing within their funding period 18 .
Furthermore, one of the main reasons for patient participation in sham surgery trials is contribution to research 19 ; if the trial is subsequently abandoned, participants are exposed to potential harm for no benefit to society, which presents an ethical dilemma.
Rationale
Therefore, in order to ensure that research funds as well as patient, surgeon and researcher time is not wasted, it is important to understand the barriers and enablers to participation in sham surgery RCTs of orthopaedic procedures. There are many publications that have considered this information, however they are diverse and at present there is no synthesis of such information specific to sham surgery trials. Furthermore, there has been no study which comprehensively evaluates the effect of the variety of factors related to sham surgical trials that influence participation of patients and surgeons. Through investigating the preferences of patients and surgeons regarding participation, we can determine the various factors necessary for a successful trial in this area; improving design, acceptability and feasibility, and ultimately patient and surgeon participation. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Aims and Objectives
The best practice method of evaluating the effect of multiple different factors on decision making is a discrete choice experiment (DCE) 20 . DCEs are used extensively in health economics and psychology to elicit individuals' preferences by presenting a series of pairs of hypothetical options. These options may be different treatment options, or in this case, different types of RCT designs. These options differ by several characteristics, referred to as attributes, for example the type of surgical procedure being tested, or the definition of sham or placebo provided to patients in participant information.
Broadly, the objective of this study is to identify and assess the literature reporting on the preferences of surgeons and patients around sham controlled trials in surgery.
Specifically, this scoping review will inform an important stage in DCE development, namely the identification and selection of appropriate attributes [21] [22] [23] . The scoping review will provide qualitative information regarding a variety of factors that affect trial recruitment.
The DCE will then provide easily translatable, quantitative information on the relative importance of each attribute in determining willingness to participate. Beyond informing DCE design, data on patient and clinician preferences are valuable to decision makers. For example preferences for outcomes can be used to inform decision and cost-effectiveness models, while preferences for treatments can inform patient-centred outcomes research and future trial design.
METHODS AND ANALYSIS

Protocol Design
We have chosen a scoping review because it is a suitable method for summarising findings from a body of knowledge that is heterogeneous in methods or discipline 24 27 . This requires identifying the research question; identifying relevant studies; study selection; charting of the data; and collating, summarising and reporting the results. To optimise reporting, this scoping review protocol uses the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols extension for Scoping Reviews (PRISMA-ScR) checklist 24 . The final review will also be reported in accordance with PRISMA-ScR. The five stages of our planned scoping review are detailed below. Title and abstract screening commenced on 26/06/2019 and data charting is to be completed by 31/01/2020. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Stage 1: Identifying the Research Question
The research questions will inform a future DCE, as well as provide important information for surgical trial design, by mapping the available evidence around the factors that affect patient and surgeon recruitment into randomised, sham controlled, surgical trials.
The key questions in this scoping review include:
1.
What characteristics of surgical trials (e.g. trial design, method of randomisation, information provided to participants) affect patient and surgeon decisions to participate in a sham surgical trial? 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Stage 3: Study Selection
The eligibility criteria were decided prior to screening and then finalised through a pilot title and abstract screen. Published primary research studies, reviews, and opinion pieces will be included in the review. Exclusion criteria included any primary research study which did not specifically deal with sham or placebo surgery, or any review or opinion publication which did not specifically address issues related placebos or participation in RCTs. Studies included in the scoping review will not be limited by year of publication. The inclusion and exclusion criteria are shown in Table 1 . Studies identified via the search strategy will be exported to EndNote X9.1 © and imported to Covidence © software 28 for the screening of titles and abstracts, and for full text review. All titles and abstracts will be independently assessed by two study authors using the selection criteria (outlined in Table   1 ), with conflicts resolved by consensus between all reviewers. Following title and abstract screening, full texts of potentially relevant studies will be independently assessed by two authors, with conflicts resolved by consensus between all reviewers. Reviewers will communicate regularly throughout the screening processes to support the iterative nature of the scoping review format, with updates to eligibility criteria as required. Any alterations made to the selection criteria as the review progresses will be recorded. The study selection process will be reported using a PRISMA flow chart diagram. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 24 , data charting is the method used for data extraction in scoping reviews. Data charting allows for a descriptive summary of the results to be collated, with amendments made to accommodate additional unforeseen data as extraction progresses. Data will be charted using a standardised electronic form, developed based on the research questions outlined above. Three authors will pilot the data charting form using the first eight studies included to ensure the data extracted addresses the research questions. This process will also ensure the data charting process is reliable among co-authors. The remainder of the data will be charted by three authors, with data extracted by one checked by a second author. Any discrepancies will be resolved by consensus among authors. The iterative nature of scoping reviews means the data charting form may require adaptation during the data charting process, which will be recorded for inclusion in the study publication.
Details and outcomes from each publication will be chosen guided by both the research questions, as well as recommendations of items to consider in data extraction published by the Cochrane collaboration 29 and Arksey and O'Malley 25 . Where available, these will include bibliographic details, study type, description of dataset used, relevant trial attributes and/or patient/surgeon attributes. Any data that informs the research questions (i.e. characteristics of trials, surgeons, or patients likely to affect trial recruitment) will be prioritised. Additional categories may be added as necessary during the full text screening, in consultation with all authors. Any other key findings or recommendations not captured through the data charting process, but which are relevant to the research questions, will be included.
All publications included in the scoping review will be critically appraised for quality.
Although not an essential part of a scoping review 24 , we will undertake this step in order to generate a level of confidence around the results, as well as to identify any gaps in the literature. Studies will not be excluded on the basis of quality appraisal score. Quantitative studies will be assessed using the Cochrane collaboration's tool for assessing risk of bias in RCTs 30 . Qualitative studies will be assessed using the Consolidated criteria for reporting qualitative studies 31 . Critical appraisal will be carried out by two reviewers independently, with discrepancies resolved by consensus amongst all authors. We recognise that in some cases, an assessment of study quality may be difficult due to the heterogeneous nature of the data sources likely to be included in this review. In the case a systematic assessment of 11 study quality is unable to be applied to a source, we will qualitatively comment on the quality of the reference included.
Stage 5: Data Summary and Synthesis of Results
The final report of our scoping review will be reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR) checklist 24 . Charted results will be summarised in the first instance to address the research questions. All data will be thematically explored and tabulated. Results of the quality assessment will be tabulated. Narrative description will also be used to aid interpretation and synthesis of results. The implications of the evidence, and any gaps in existing knowledge, will also be summarised narratively. The key findings from this review will inform the development of attributes and levels for a DCE investigating factors precluding participation in RCTs of orthopaedic procedures. The main findings, as well as gaps in knowledge identified throughout the review, will be used to help develop questionnaires and focus group materials, to be supplied to representatives of the populations of interest in order to further identify and develop attributes for the DCE.
The inclusion of evidence across a wide range of sources ensures that this review will report a widespread range of attributes relating to trials, patients, and surgeons likely to affect recruitment to clinical trials of surgery. The results of this review may be used more broadly to inform future trial design, both within and outside of surgery.
Strengths and Limitations.
A strength of this scoping review is the breadth and diversity of articles to be included. Previous reviews on factors affecting recruitment of RCTs have only included experimental studies, surveys, questionnaires and interviews. Although these generally provide higher quality data than expert opinion, they are limited in the data they provide by what questions were asked. More general review or opinion pieces are not restricted to focus on only a few key items and thus can explore a greater number of themes that may potentially affect recruitment. As the results of this scoping article will inform qualitative interviews initially, and then a comprehensive DCE, it is important that all possible barriers and enablers to recruitment are included in this review, to be narrowed down through patient and surgeon interviews. This will ensure that the DCE is optimally designed.
A limitation of this scoping review is that we will not collect grey literature, unpublished work, or work written in languages other than English. There is a risk that some crucial attributes will not have been published in English, in peer reviewed journals or in any form previously and therefore will not be captured in this review. Further, there is a risk that published opinion pieces will primarily reflect one point of view. Therefore, additional attributes will be identified in qualitative interviews to occur subsequent to the scoping review, which will also be used to inform development of the DCE. To address these limitations and further inform the development of the DCE, we plan to conduct qualitative interviews with patients and surgeons about their preferences for participation in a sham surgery trial. These and other limitations identified throughout the review process will be acknowledged in the review publication.
Patient and Public Involvement
There will be no patient or public involvement in this scoping review.
Ethics and Dissemination
The final scoping review will be submitted for publication in a peer review journal and may also be presented at appropriate forums or conferences. Findings will be used to inform the development of a DCE to investigate patient and surgeon preferences around randomised controlled trials in orthopaedic surgery. As a synthesis of published studies and other references, no ethics approval is required. There is no data currently available for this paper as it is a protocol, however the data sourced throughout the scoping review will be made available in an open repository at the time of publication.
DISCUSSION
Clinical trials in orthopaedic surgery are becoming more frequent worldwide, and it is of vital importance to address the poor recruitment and retention rates commonly associated with them. At present, surgical trials which do not reach their minimum recruitment levels are associated with significant concerns about their validity and applicability, and cannot therefore answer questions about the efficacy of some procedures.
To our knowledge there have been no other similar reviews of attributes affecting recruitment into sham surgery trials. The results of this review will have implications beyond informing our future DCE. The comprehensive inclusion of previous studies, opinions, and ethical viewpoints will also benefit other researchers wishing to design DCEs regarding sham surgery, but also more broadly provide a summary of trial, patient, and surgeon 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Search Strategy: 38 limit 37 to english language (1036) *************************** Database: Embase <1947 to present> Search Strategy: Search Strategy: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46 15d If quantitative synthesis is not appropriate, describe the type of summary planned 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45 The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence -details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.
Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Data will be charted using a standardised form, and results tabulated and narratively summarised with reference to the research questions of the review.
Ethics and Dissemination.
The findings from this review will inform the design of a discrete choice experiment around willingness to participate in surgical trials, the outcomes of which can inform decision and cost-effectiveness models of sham surgery RCTs. The qualitative information from this review will also inform patient-centred outcomes research. The review will be published in a peer reviewed journal. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  To capture all possible factors affecting recruitment of RCTs this review will not restrict the inclusion criteria to only surveys and interviews, which are limited in the information they provide by the questions they ask, but will also include published reviews and expert opinion, which can explore a greater number of themes.
Limitations  This scoping review will not collect grey literature, unpublished work, or work written in languages other than English.
 The breadth of inclusion criteria, allowing published opinion pieces, introduces a risk that these pieces will primarily reflect one point of view.
INTRODUCTION Background
The double blinded randomised controlled trial is the 'gold standard' of medical research and recommended across a range of fields for assessing new interventions [1] [2] [3] . This process is more difficult however when the intervention is surgical. The surgeon can never be fully blinded and the extent to which the placebo resembles the surgery is practically and ethically problematic 4 . There is some inconsistency in the requirements of a 'sham' surgery however the definition we will use throughout this review is the same as Jonas et al. (2015, p.3), who define an invasive surgical procedure as a procedure where "an instrument is inserted into the body … for the purpose of manipulating tissue or changing anatomy" 5 , and a sham procedure as one that involves the same surgical or invasive procedure with associated instruments and ritual, but without the critical component of tissue manipulation.
The use of sham and placebo surgeries in surgical trials is controversial. Some commentators have argued that surgical placebos are essential, and that surgical interventions should be held to the same rigorous assessment as other medical procedures 6 7 , particularly given the expense and risks involved with untested surgical procedures 8 9 .
However, others have argued it is misguided to consider sham surgery as analogous to sugar 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 4 pills due to the increased risks and harm to participants without any benefit [10] [11] [12] and as such consider sham surgery to be unjustified and unethical.
These issues have become particularly significant in orthopaedic surgery, with the efficacy of some orthopaedic procedures being called into question. Recent observational studies have shown that a significant proportion of patients report no clinical meaningful improvement in pain or function after knee replacement surgery 13 14 . Further, several recent systematic reviews of RCTs in orthopaedic surgery have suggested that surgery is no better than a sham procedure in reducing pain 5 9 15 , although firm conclusions regarding efficacy are constrained by limitations of the trials including incomplete recruitment 5 . In a number of countries worldwide, orthopaedic surgeries are high volume and expensive procedures, with considerable risks and significant recovery times for patients 16 . Therefore, there is increasing pressure to improve the evidence base around orthopaedic surgical procedures. In order to properly evaluate the efficacy of orthopaedic procedures, rigorous randomised controlled trial (RCT) designs, blinded through sham surgery, are necessary.
There is evidence to suggest that the number of RCTs in surgery is increasing, however their use in comparison to other study types remains low 17 18 . Furthermore, RCTs for surgery involving a sham procedure are not only ethically debated but they are also difficult to conduct with most trials not reaching their desired sample size for sufficient power 8 .
A recent systematic review conducted by the authors on sham surgery trials in orthopaedics found that none out of ten trials had some risk of bias, and in two trials the benefits of the sham procedure were not considered to outweigh the risks involved 8 .
Furthermore, it was found that participant recruitment within reasonable timeframes and low threshold for crossover were consistent challenges. This highlighted that there were considerable issues around the feasibility of such trials. This is symptomatic of clinical trials generally, with up to 50% of funded trials not publishing within their funding period 19 . As one of the main reasons for patient participation in sham surgery trials is contribution to research 20 , if the trial is subsequently abandoned, participants are exposed to potential harm for no benefit to society, which presents an ethical dilemma.
In order to ensure that research funds as well as patient, surgeon and researcher time are not wasted, it is important to understand both the challenges and feasibility of conducting a sham surgery trial within the anticipated timeframe, and the barriers and enablers to participation in sham surgery RCTs of orthopaedic procedures. In order to more thoroughly explore the feasibility of sham surgery trials a follow up systematic review by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 5 members of this research team is currently being conducted, to investigate any disparity between planned (protocol and trial registry) and actual (outcome papers) outcomes from sham surgery trials (registered on Prospero CRD42019133296). This review will identify potential trial characteristics associated with differences in recruitment rates, however it is also considered important to identify information regarding patient and surgeon preferences for trial participation.
Rationale
To date, there has been no study which comprehensively evaluates the effect of the variety of factors related to sham surgery trials that influences participation decisions of patients and surgeons. Through investigating the preferences of patients and surgeons regarding participation, we can determine the various factors necessary for a successful trial in this area; improving design, acceptability and feasibility, and ultimately patient and surgeon participation. The best practice method of evaluating the effect of multiple factors on decision making is a discrete choice experiment (DCE) 21 .
DCEs are used extensively in economics and psychology to elicit individuals' preferences by presenting a series of pairs of hypothetical options. These may be different treatment options, or in this case, different types of RCT designs. These options differ by several characteristics, referred to as attributes, for example the type of surgical procedure being tested, or the definition of sham or placebo provided to patients in participant information. The usefulness of a DCE relies heavily on appropriate design, in particular the selection of suitable attributes. The recommended guidelines for the design of DCEs indicate that the selection of attributes should be informed by multiple sources, including literature reviews and focus groups [22] [23] [24] .
Therefore, this paper outlines a protocol for a scoping review mapping factors that influence patient and surgeon decision making around sham surgical trials in orthopaedics, which will ultimately be used to inform a DCE to empirically test patient and surgeon preferences for different sham surgery trial designs. In keeping with the methodological recommendations for the conduct of DCEs, a series of qualitative interviews and focus groups with key stakeholders, including orthopaedic patients and surgeons, will then inform the selection of identified attributes to be included in the final DCE. To our knowledge, evidence synthesis around preferences for surgical trials has not been previously published. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Therefore, this scoping review will also inform future patient-centred outcomes research around sham surgery trials.
Aims and Objectives
Broadly, the objective of this study is to identify and assess the literature reporting on the preferences of surgeons and patients around sham controlled trials in surgery. Specifically, this scoping review will inform an important stage in DCE development, namely the identification and selection of appropriate attributes [25] [26] [27] . The scoping review will provide qualitative information regarding a variety of factors that affect trial recruitment. The DCE will then provide easily translatable, quantitative information on the relative importance of each attribute in determining willingness to participate. Beyond informing DCE design, data on patient and clinician preferences are valuable to decision makers 28 29 . For example preferences for outcomes can be used to inform decision and costeffectiveness models, while preferences for treatments can inform patient-centred outcomes research and future trial design.
METHODS AND ANALYSIS
Protocol Design
We have chosen a scoping review because it is a suitable method for summarising findings from a body of knowledge that is heterogeneous in methods or discipline 30 . The framework for our scoping review will be compiled in accordance with Arksey and O'Malley 31 , Levac, Colquhoun, and O'Brien 32 and Peters et al. 33 . This requires identifying the research question; identifying relevant studies; study selection; charting of the data; and collating, summarising and reporting the results. To optimise reporting, this scoping review protocol uses the Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols extension for Scoping Reviews (PRISMA-ScR) checklist 30 . The final review will also be reported in accordance with PRISMA-ScR. The five stages of our planned scoping review are detailed below. Title and abstract screening commenced on 26/06/2019 and data charting is to be completed by 31/01/2020.
Stage 1: Identifying the Research Question
The research questions will inform a future DCE, as well as provide important information for surgical trial design, by mapping the available evidence around the factors 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The key questions in this scoping review include:
1.
What characteristics of surgical trials (e.g. trial design, method of randomisation, information provided to participants) affect patient and surgeon decisions to participate in a sham surgical trial?
2.
What patient characteristics (e.g. level of pain, perceived time costs) affect their decision to participate in a sham surgical trial?
3.
What surgeon characteristics (e.g. seniority, previous participation in research) affect their decision to participate in a sham surgical trial?
Stage 2: Identifying Relevant Studies
We conducted a systematic search of the Medline, Embase, PsycInfo, Cinahl, and
EconLit databases from database inception to the 21 st (Medline, Embase and PyscInfo) and 
Stage 3: Study Selection
The eligibility criteria were decided prior to screening and then finalised through a pilot title and abstract screen. The inclusion and exclusion criteria are shown in Table 1 .
Inclusion criteria will include published primary research studies, reviews, and opinion pieces. Exclusion criteria will include any primary research study which does not specifically 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 8 deal with sham or placebo surgery, or any review or opinion publication which does not specifically address issues related to placebos or participation in RCTs. Studies included in the scoping review will not be limited by year of publication. Studies identified via the search strategy will be exported to EndNote X9.1 © and imported to Covidence © software 34 for the screening of titles and abstracts, and for full text review. All titles and abstracts will be independently assessed by two study authors using the selection criteria (outlined in Table 1 ), with conflicts resolved by consensus between all reviewers. Following title and abstract screening, full texts of potentially relevant studies will be independently assessed by two authors, with conflicts resolved by consensus between all reviewers. Reviewers will communicate regularly throughout the screening processes to support the iterative nature of the scoping review format, with updates to eligibility criteria as required. Any alterations made to the selection criteria as the review progresses will be recorded. The study selection process will be reported using a PRISMA flow chart diagram. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Table 1 Table of inclusion and exclusion criteria for the title and abstract, and full text screening 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 30 , data charting is the method used for data extraction in scoping reviews. Data charting allows for a descriptive summary of the results to be collated, with amendments made to accommodate additional unforeseen data as extraction progresses. Data will be charted using a standardised electronic form, developed based on the research questions outlined above. Three authors will pilot the data charting form using the first eight studies included to ensure the data extracted addresses the research questions. This process will also ensure the data charting process is reliable among co-authors. The remainder of the data will be charted by three authors, with data extracted by one checked by a second author. Any discrepancies will be resolved by consensus among authors. The iterative nature of scoping reviews means the data charting form may require adaptation during the data charting process, which will be recorded for inclusion in the study publication.
Details and outcomes from each publication will be chosen guided by both the research questions, as well as recommendations of items to consider in data extraction published by the Cochrane collaboration 35 and Arksey and O'Malley 31 . Where available, these will include bibliographic details, study type, description of dataset used, relevant trial attributes and/or patient/surgeon attributes. Any data that informs the research questions (i.e. characteristics of trials, surgeons, or patients likely to affect trial recruitment) will be prioritised. Additional categories may be added as necessary during the full text screening, in consultation with all authors. Any other key findings or recommendations not captured through the data charting process, but which are relevant to the research questions, will be included.
Although not an essential part of a scoping review 30 , we will undertake this step to generate a level of confidence around the results, as well as to identify any gaps in the literature.
Studies will not be excluded on the basis of quality appraisal score. Quantitative studies will be assessed using the Cochrane collaboration's tool for assessing risk of bias in RCTs 36 .
Qualitative studies will be assessed using the Consolidated criteria for reporting qualitative studies 37 . Critical appraisal will be carried out by two reviewers independently, with discrepancies resolved by consensus amongst all authors. We recognise that in some cases, an assessment of study quality may be difficult due to the heterogeneous nature of the data sources likely to be included in this review. In the case a systematic assessment of study 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   11 quality is unable to be applied to a source, we will qualitatively comment on the quality of the reference included.
Stage 5: Data Summary and Synthesis of Results
The outcomes of this scoping review will be reported according to the PRISMA Extension for Scoping Reviews (PRISMA-ScR) checklist 30 . Charted results will be summarised in the first instance to address the research questions. All data will be thematically explored and tabulated. Results of the quality assessment will be tabulated. Narrative description will also be used to aid interpretation and synthesis of results. The implications of the evidence, and any gaps in existing knowledge, will also be summarised narratively. The key findings from this review will inform the development of attributes and levels for a DCE investigating factors precluding participation in RCTs of orthopaedic procedures.
Strengths and Limitations.
A strength of this scoping review is the breadth and diversity of articles to be included. Previous reviews on factors affecting recruitment of RCTs have only included experimental studies, surveys, questionnaires and interviews. Although these generally provide higher quality data than expert opinion, they are limited in the data they provide by what questions were asked. More general review or opinion pieces are not restricted to focus on only a few key items and thus can explore a greater number of themes that may potentially affect recruitment. As the results of this scoping review are intended to be the primary information in the design of a comprehensive DCE (supplemented by qualitative interviews and a related systematic review), it is important that all possible barriers and enablers to recruitment are included in. This will ensure that the DCE is optimally designed.
A limitation of this scoping review is that we will not collect grey literature, unpublished work, or work written in languages other than English. There is a risk that some crucial attributes will not have been published in English, in peer reviewed journals or in any form previously and therefore will not be captured in this review. Further, there is a risk that published opinion pieces will primarily reflect one point of view. However the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 12 supplementary patient and surgeon qualitative interviews should help to address these limitations. These and other limitations identified throughout the review process will be acknowledged in the review publication.
Patient and Public Involvement
Ethics and Dissemination
The final scoping review will be submitted for publication in a peer review journal and may also be presented at appropriate forums or conferences. Findings will be used to inform the There is no data currently available for this paper as it is a protocol, however the data sourced throughout the scoping review will be made available in an open repository at the time of publication.
DISCUSSION
Sham clinical trials in orthopaedic surgery are becoming more frequent worldwide, and it is of vital importance to address the poor recruitment and retention rates commonly associated with them. At present, sham surgical trials which do not reach their minimum recruitment levels are associated with significant concerns about their validity and applicability, and therefore cannot answer questions about the efficacy of some procedures.
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Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
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Study records: Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review Page 6 in section 'stage 3: study selection'
Selection process 11b
State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Page 6 in section 'stage 3: study selection'
Data collection process 11c
Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators Page 8 in section 'stage 4: data charting'
Data items 12
List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications Page 8 in section 'stage 4: data charting' and in table 1 on page 7
Outcomes and prioritisation 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Page 8 in section 'stage 4: data charting'
Risk of bias in individual studies 14
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